Literature DB >> 7594546

Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.

L Ramarathinam1, S Sarma, M Maric, M Zhao, G Yang, L Chen, Y Liu.   

Abstract

Whether tumors of different lineages share common Ags is a critical issue for understanding anti-tumor immune responses and for designing Ag-specific tumor immunotherapy. Because of lack of cross-protection among individually derived tumors, it has been proposed that tumor Ags are specific for individual tumors. Here we show that lack of cross-protection is not due to lack of a shared tumor Ag. Thus, a plasmocytoma J558 transfected with the costimulatory molecule B7 activates a cross-reactive CTL response in vivo. The major Ag recognized by the cross-reactive CTL is P1A, which is expressed in mastocytoma P815, plasmocytoma J558, and fibrosarcoma Meth A. Surprisingly, no significant cross-protection can be detected among P1A-expressing tumors after immunization with either P1A-expressing or B7-transfected P815 cells. Our results demonstrate that multiple lineages of tumors are not cross-protected even though they share a tumor Ag that can be recognized by CTL. These results have important implications for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594546

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 3.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

4.  B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.

Authors:  P Zheng; Y Wu; Y Guo; C Lee; Y Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

Authors:  Pawel Mroz; Fatma Vatansever; Angelika Muchowicz; Michael R Hamblin
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

Review 6.  Stimulation of anti-tumor immunity by photodynamic therapy.

Authors:  Pawel Mroz; Javad T Hashmi; Ying-Ying Huang; Norbert Lange; Michael R Hamblin
Journal:  Expert Rev Clin Immunol       Date:  2011-01       Impact factor: 4.473

7.  De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

Authors:  Z Sheng Guo; Julie A Hong; Kari R Irvine; G Aaron Chen; Paul J Spiess; Yang Liu; Gang Zeng; John R Wunderlich; Dao M Nguyen; Nicholas P Restifo; David S Schrump
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

8.  5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

Authors:  Malgorzata Wachowska; Magdalena Gabrysiak; Angelika Muchowicz; Weronika Bednarek; Joanna Barankiewicz; Tomasz Rygiel; Louis Boon; Pawel Mroz; Michael R Hamblin; Jakub Golab
Journal:  Eur J Cancer       Date:  2014-02-18       Impact factor: 9.162

9.  Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis.

Authors:  Chi-Shan Li; Chong Chen; Pan Zheng; Yang Liu
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

10.  Trap1a is an X-linked and cell-intrinsic regulator of thymocyte development.

Authors:  Chi-Shan Li; Fei Tang; Peng Zhang; Taijiao Jiang; Thomas L Saunders; Pan Zheng; Yang Liu
Journal:  Cell Mol Immunol       Date:  2016-04-11       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.